IRVINE, Calif., May 26, 2009 (GLOBE NEWSWIRE) -- SenoRx (Nasdaq:SENO) today announced that three oral presentations summarizing clinical findings related to its Contura(tm) Multi-Lumen Balloon (MLB) Catheter will be delivered at the American Brachytherapy Society Annual Meeting being held May 31 through June 2, 2009 in Toronto, Canada.
"Dedicated to advancing the field of brachytherapy, ABS provides a targeted forum to present the latest research on brachytherapy to key opinion leaders from major universities and certain institutions active in clinical research," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "SenoRx is pleased to again participate in the annual conference and to have clinical research related to Contura MLB presented to ABS members who represent leading specialists in the field of brachytherapy."
Malchow continued, "The three scheduled presentations, along with other studies, continue to support our belief that a patient treated with Contura MLB can receive a more targeted dose of radiation, while minimizing radiation to healthy tissue such as the skin and ribs."
Presentations to be delivered at the ABS conference are:
"Initial Dosimetric Experience: Contura Multi-Lumen Balloon (MLB) Registry Trial" -- Authors: Arthur, D.W.; Vicini, F.A.; Todor, D.; and Julian, T.B. -- to be presented at American Brachytherapy Society (ABS), June 2009. The conclusion of this study is that without the dosimetric optimizing capabilities, the safe use of a single lumen balloon is limited to patients with ideal cavity geometry and balloon symmetry. This initial comparison shows that the use of multiple, off-set lumens allow the optimization of target coverage while minimizing dose to nearby skin and chest wall, thus creating a new improved dosimetric standard.
"A Comparison of Skin and Chest Wall Dose Delivered with Multi-Catheter (MC), Contura Multi-Lumen Balloon (MLB), and MammoSite (MS) Breast Brachytherapy" -- Authors: Cuttino, L.W.; Todor, D.T.; Heffernan, J.; Vera, R.; and Arthur, D.W. -- to be presented at American Brachytherapy Society (ABS), June 2009. The conclusion of this study is that the multi-catheter and Contura MLB techniques are associated with significantly lower mean skin and chest wall doses than with MammoSite, which was associated with significantly more patients receiving doses to these areas in excess of 125 percent of the prescription dose. Doses delivered with Contura MLB were more similar to those of the multi-catheter technique, which is associated with a very low incidence of skin and chest wall toxicity, suggesting treatment with Contura MLB may prove to be better tolerated.
"Verification of Balloon Rotation for the Contura Multi-Lumen Device for Accelerated Partial Breast Irradiation" -- Authors: Ouhib Z., Benda, R., Kasper, M., Vargas, C. -- to be presented at American Brachytherapy Society (ABS), June 2009. The conclusion of this study confirms that the alignment of the skin mark with lumen #1 can be a reliable tool to align the balloon prior to treatment and also that no internal device rotation or torquing is likely to occur. This is critical for the MLB as there may be significant variability in dwell times between catheters and various dwell points within a catheter to allow for skin and/or rib sparing while maintaining adequate dose coverage.
Malchow added, "These studies along with others already published or presented are helpful in supporting our ongoing promotion of Contura MLB. We are also pleased that over 30 sites are participating in our Contura MLB Registry Study in which 156 patients have now enrolled."
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605